Savage et al. employ whole-genome, transcriptome sequencing and reverse-phase protein arrays on 37 developed breast cancer patient-derived xenografts (PDX) models to identify potential therapeutic targets, metastatic potential and chemosensitivity. This PDX library with comprehensive molecular and phenotypic profiling could serve as a resource for preclinical studies on difficult-to-treat breast tumors.
- Paul Savage
- Alain Pacis
- Morag Park
